Cited by 372Gastrointestinal motility and disordersIon Channels and ReceptorsPain Mechanisms and Treatments

Histamine Receptor H1–Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome

Open access
Wouters, Mira M., Balemans, Dafne, Van Wanrooy, Sander, Dooley, James, Cibert-Goton, Vincent, Alpizar, Yeranddy A., Valdez-Morales, Eduardo E., Nasser, Yasmin +20 more·2016·Gastroenterology

Abstract

Background & aims Histamine sensitizes the nociceptor transient reporter potential channel V1 (TRPV1) and has been shown to contribute to visceral hypersensitivity in animals. We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antagonist of histamine receptor H1 (HRH1) could reduce symptoms of patients in a randomized placebo-controlled trial.Methods By using live calcium imaging, we compared activation of submucosal neurons by the TRPV1 agonist capsaicin in rectal biopsy specimens collected from 9 patients with IBS (ROME 3 criteria) and 15 healthy subjects. The sensitization of TRPV1 by histamine, its metabolite imidazole acetaldehyde, and supernatants from biopsy specimens was assessed by calcium imaging of mouse dorsal root ganglion neurons. We then performed a double-blind trial of patients with IBS (mean age, 31 y; range, 18-65 y; 34 female). After a 2-week run-in period, subjects were assigned randomly to groups given either the HRH1 antagonist ebastine (20 mg/day; n = 28) or placebo (n = 27) for 12 weeks. Rectal biopsy specimens were collected, barostat studies were performed, and symptoms were assessed (using the validated gastrointestinal symptom rating scale) before and after the 12-week period. Patients were followed up for an additional 2 weeks. Abdominal pain, symptom relief, and health-related quality of life were assessed on a weekly basis. The primary end point of the study was the effect of ebastine on the symptom score evoked by rectal distension.Results TRPV1 responses of submucosal neurons from patients with IBS were potentiated compared with those of healthy volunteers. Moreover, TRPV1 responses of submucosal neurons from healthy volunteers could be potentiated by their pre-incubation with histamine; this effect was blocked by the HRH1 antagonist pyrilamine. Supernatants from rectal biopsy specimens from patients with IBS, but not from the healthy volunteers, sensitized TRPV1 in mouse nociceptive dorsal root ganglion neurons via HRH1; this effect could be reproduced by histamine and imidazole acetaldehyde. Compared with subjects given placebo, those given ebastine had reduced visceral hypersensitivity, increased symptom relief (ebastine 46% vs placebo 13%; P = .024), and reduced abdominal pain scores (ebastine 39 ± 23 vs placebo 62 ± 22; P = .0004).Conclusions In studies of rectal biopsy specimens from patients, we found that HRH1-mediated sensitization of TRPV1 is involved in IBS. Ebastine, an antagonist of HRH1, reduced visceral hypersensitivity, symptoms, and abdominal pain in patients with IBS. Inhibitors of this pathway might be developed as a new treatment approach for IBS. ClinicalTrials.gov no: NCT01144832.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2015.12.034

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a small RCT in 45 patients, the histamine 1 receptor antagonist ebastine led to significant improvements in both abdominal pain and global symptoms.

    “in a small RCT in 45 patients the histamine 1 receptor antagonist ebastine led to significant improvements in both abdominal pain and global symptoms.290”

    From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [290]

    The trial-results section reports significantly greater global symptom relief and lower abdominal pain scores with ebastine than with placebo at week 12. The stated trial size is incorrect: 55 patients were randomized, not 45 (51 completed treatment). No page number is available in our copy. (LLM, conf=0.92)

    Experimental — accuracy not yet measured
  • These mast cell mediators may alter nociceptive pathways in IBS or increase intestinal permeability.

    “These mediators may alter nociceptive pathways in IBS115 or increase intestinal permeability116.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [38]38. Valdez-Morales EE, Overington J, Guerrero-Alba R, et al. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. Am J Gas- troenterol 2013;108:1634-1643.
  2. [40]40. Cirillo C, Tack J, Vanden Berghe P. Nerve activity re- cordings in routine human intestinal biopsies. Gut 2013; 62:227-235.
  3. [47]47. Longstreth GF, Thompson WG, Chey WD, et al. Func- tional bowel disorders. Gastroenterology 2006; 130:1480-1491.
  4. [48]48. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irri- table bowel syndrome. Gut 2010;59:1213-1221.
  5. [49]49. Kuiken SD, Lindeboom R, Tytgat GN, et al. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:157-164.

Cited by

Sorted by citations

Authors
Wouters, M. M., Balemans, D., Van Wanrooy, S., Dooley, J., Cibert-Goton, V., Alpizar, Y. A., Valdez-Morales, E. E., Nasser, Y., Van Veldhoven, P. P., Vanbrabant, W., Van der Merwe, S., Mols, R., Ghesquière, B., Cirillo, C., Kortekaas, I., Carmeliet, P., Peetermans, W. E., Vermeire, S., Rutgeerts, P., Augustijns, P., Hellings, P. W., Belmans, A., Vanner, S., Bulmer, D. C., Talavera, K., Vanden Berghe, P., Liston, A., & Boeckxstaens, G. E.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • VIB-KU Leuven Center for Microbiology (BE)
  • KU Leuven (BE)
  • Queen's University (CA)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Queen Mary University of London (GB)
Corresponding author
Boeckxstaens, Guy E.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2016-04
Volume
150
Issue
4
Pages
875-887.e9
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2203163745
Cited by
372
References
46
Citations by year
2026: 22 · 2025: 33 · 2024: 42 · 2023: 39 · 2022: 32 · 2021: 49 · 2020: 39 · 2019: 24 · 2018: 38 · 2017: 37 · 2016: 15 · 2014: 1
FWCI
41.60
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Lirias (submittedVersion)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Bowel and Cancer Research (1119105)
  • Canadian Association of Gastroenterology
  • KU Leuven (GOA 14.011)
  • Crohn's and Colitis Canada
  • Vlaamse regering
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
Keywords
irritable bowel syndrome, TRPV1, visceral hypersensitivity, ebastine, mepyramine, capsaicin, submucosal neurons, dorsal root ganglion neurons, rectal distension, abdominal pain, histamine sensitization, health-related quality of life, gastrointestinal symptoms, barostat, calcium imaging
MeSH terms
Adolescent, Adult, Aged, Analgesics, Belgium, Biopsy, Butyrophenones, Double-Blind Method, Female, Gastrointestinal Agents, Histamine H1 Antagonists, Humans, Male, Middle Aged, Neurons, Pain Measurement, Piperidines, Quality of Life, Surveys and Questionnaires, Receptors, Histamine H1, Rectum, Remission Induction, Time Factors, Abdominal Pain, Treatment Outcome, Pain Threshold, Calcium Signaling, Receptor Cross-Talk, Irritable Bowel Syndrome, TRPV Cation Channels, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review